<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39433939</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-1784</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature reviews. Drug discovery</Title><ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation></Journal><ArticleTitle>Advanced technologies for the development of infectious disease vaccines.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41573-024-01041-z</ELocationID><Abstract><AbstractText>Vaccines play a critical role in the prevention of life-threatening infectious disease. However, the development of effective vaccines against many immune-evading pathogens such as HIV has proven challenging, and existing vaccines against some diseases such as tuberculosis and malaria have limited efficacy. The historically slow rate of vaccine development and limited pan-variant immune responses also limit existing vaccine utility against rapidly emerging and mutating pathogens such as influenza and SARS-CoV-2. Additionally, reactogenic effects can contribute to vaccine hesitancy, further undermining the ability of vaccination campaigns to generate herd immunity. These limitations are fuelling the development of novel vaccine technologies to more effectively combat infectious diseases. Towards this end, advances in vaccine delivery systems, adjuvants, antigens and other technologies are paving the way for the next generation of vaccines. This Review focuses on recent advances in synthetic vaccine systems and their associated challenges, highlighting innovation in the field of nano- and nucleic acid-based vaccines.</AbstractText><CopyrightInformation>© 2024. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Akash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rudra</LastName><ForeName>Arnab</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1704-5534</Identifier><AffiliationInfo><Affiliation>David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Reed</LastName><ForeName>Kaelan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4255-0492</Identifier><AffiliationInfo><Affiliation>David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard and MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials><Identifier Source="ORCID">0000-0001-5629-4798</Identifier><AffiliationInfo><Affiliation>David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. dgander@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. dgander@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA. dgander@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard and MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA. dgander@mit.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. dgander@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Drug Discov</MedlineTA><NlmUniqueID>101124171</NlmUniqueID><ISSNLinking>1474-1776</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39433939</ArticleId><ArticleId IdType="doi">10.1038/s41573-024-01041-z</ArticleId><ArticleId IdType="pii">10.1038/s41573-024-01041-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morens, D. M. &amp; Fauci, A. S. Emerging pandemic diseases: how we got to COVID-19. Cell 182, 1077–1092 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32846157</ArticleId><ArticleId IdType="pmc">7428724</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Toor, J. et al. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. eLife 10, e67635 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34253291</ArticleId><ArticleId IdType="pmc">8277373</ArticleId><ArticleId IdType="doi">10.7554/eLife.67635</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan, V. Y., Jamison, D. T. &amp; Summers, L. H. Pandemic risk: how large are the expected losses? Bull. World Health Organ. 96, 129–134 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29403116</ArticleId><ArticleId IdType="doi">10.2471/BLT.17.199588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascola, J. R. &amp; Fauci, A. S. Novel vaccine technologies for the 21st century. Nat. Rev. Immunol. 20, 87–88 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31712767</ArticleId><ArticleId IdType="doi">10.1038/s41577-019-0243-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Excler, J. L., Saville, M., Berkley, S. &amp; Kim, J. H. Vaccine development for emerging infectious diseases. Nat. Med. 27, 591–600 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33846611</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01301-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebre, M. S. et al. Novel approaches for vaccine development. Cell 184, 1589–1603 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33740454</ArticleId><ArticleId IdType="pmc">8049514</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.02.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes, B. F. et al. Prospects for a safe COVID-19 vaccine. Sci. Transl. Med. 12, eabe0948 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33077678</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abe0948</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth, G. A. et al. Designing spatial and temporal control of vaccine responses. Nat. Rev. Mater. 7, 174–195 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34603749</ArticleId><ArticleId IdType="doi">10.1038/s41578-021-00372-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirelli, K. M. et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell 177, 1153–1171.e28 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31080066</ArticleId><ArticleId IdType="pmc">6619430</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.04.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Satti, I. et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect. Dis. 14, 939–946 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25151225</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(14)70845-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–5714.e11 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34735795</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.10.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, C. J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239–252 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32060419</ArticleId><ArticleId IdType="doi">10.1038/s41573-019-0056-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med. 29, 247–257 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36265510</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02092-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, B. S., Gilman, M. S. A. &amp; McLellan, J. S. Structure-based vaccine antigen design. Annu. Rev. Med. 70, 91–104 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30691364</ArticleId><ArticleId IdType="doi">10.1146/annurev-med-121217-094234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O. &amp; De Gregorio, E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469–481 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27022144</ArticleId><ArticleId IdType="doi">10.1084/jem.20151960</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi, N., Hogan, M. J., Porter, F. W. &amp; Weissman, D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29326426</ArticleId><ArticleId IdType="doi">10.1038/nrd.2017.243</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615–632 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32887954</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-00434-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat. Nanotechnol. 16, 16–24 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33199883</ArticleId><ArticleId IdType="doi">10.1038/s41565-020-00790-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine, D. J., Swartz, M. A. &amp; Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12, 978–990 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24150416</ArticleId><ArticleId IdType="doi">10.1038/nmat3775</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeke, R., Hogan, M. J., Loré, K. &amp; Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993–2005 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36351374</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2022.10.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond, M. S. &amp; Kanneganti, T.-D. Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol. 23, 165–176 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35105981</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziogas, A. &amp; Netea, M. G. Trained immunity-related vaccines: innate immune memory and heterologous protection against infections. Trends Mol. Med. 28, 497–512 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35466062</ArticleId><ArticleId IdType="doi">10.1016/j.molmed.2022.03.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A. &amp; Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 18, 553–566 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30967658</ArticleId><ArticleId IdType="doi">10.1038/s41573-019-0025-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasteiger, G. et al. Cellular innate immunity: an old game with new players. J. Innate Immun. 9, 111–125 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28006777</ArticleId><ArticleId IdType="doi">10.1159/000453397</ArticleId></ArticleIdList></Reference><Reference><Citation>Worbs, T., Hammerschmidt, S. I. &amp; Förster, R. Dendritic cell migration in health and disease. Nat. Rev. Immunol. 17, 30–48 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27890914</ArticleId><ArticleId IdType="doi">10.1038/nri.2016.116</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartz, M. A., Hubbell, J. A. &amp; Reddy, S. T. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin. Immunol. 20, 147–156 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18201895</ArticleId><ArticleId IdType="doi">10.1016/j.smim.2007.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch, S., Jasny, E., Schmidt, K. E. &amp; Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30283434</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.01963</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, J. T., Marks, P., Goldstein, R. H. &amp; Walensky, R. P. Intradermal vaccination for monkeypox — benefits for individual and public health. N. Engl. J. Med. 387, 1151–1153 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36044621</ArticleId><ArticleId IdType="doi">10.1056/NEJMp2211311</ArticleId></ArticleIdList></Reference><Reference><Citation>Alu, A. et al. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine 76, 103841 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35085851</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.103841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull, N. C. et al. Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1<sup>+</sup> KLRG1<sup>−</sup> CD4<sup>+</sup> T cells. Mucosal Immunol. 12, 555–564 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30446726</ArticleId><ArticleId IdType="doi">10.1038/s41385-018-0109-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, J. et al. Airway memory CD4<sup>+</sup> T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379–1391 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27287409</ArticleId><ArticleId IdType="pmc">4917442</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2016.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter, N. J. &amp; Curran, M. P. Live attenuated influenza vaccine (FluMist®; Fluenz<sup>TM</sup>). Drugs 71, 1591–1622 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21861544</ArticleId><ArticleId IdType="doi">10.2165/11206860-000000000-00000</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldeon Vaca, G. et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci. Adv. 9, eadh1655 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37738334</ArticleId><ArticleId IdType="pmc">10516494</ArticleId><ArticleId IdType="doi">10.1126/sciadv.adh1655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abo2523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwell, B. L. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci. Transl. Med. 14, eabn1413 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn1413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganley, M. et al. mRNA vaccine against malaria tailored for liver-resident memory T cells. Nat. Immunol. 24, 1487–1498 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37474653</ArticleId><ArticleId IdType="doi">10.1038/s41590-023-01562-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Darrah, P. A. et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 577, 95–102 (2020). This study investigates the association between BCG vaccine efficacy and its administration route, revealing that intravenous BCG provides exceptional protection against Mycobacterium tuberculosis infection.</Citation><ArticleIdList><ArticleId IdType="pubmed">31894150</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1817-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326–3334 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31079849</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2019.04.074</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins, M. L. M. et al. Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial. NPJ Vaccines 9, 1 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38167735</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00785-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Syenina, A. et al. Adverse effects following anti–COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes. PLoS Biol. 20, e3001643 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35639676</ArticleId><ArticleId IdType="pmc">9154185</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.3001643</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshaghi, B. et al. The role of engineered materials in mucosal vaccination strategies. Nat. Rev. Mater. 9, 29–45 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-023-00625-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501–1505 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32703906</ArticleId><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId></ArticleIdList></Reference><Reference><Citation>McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24179220</ArticleId><ArticleId IdType="pmc">4461862</ArticleId><ArticleId IdType="doi">10.1126/science.1243283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, M. et al. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc. Natl Acad. Sci. USA 119, e2110105119 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35994646</ArticleId><ArticleId IdType="pmc">9436349</ArticleId><ArticleId IdType="doi">10.1073/pnas.2110105119</ArticleId></ArticleIdList></Reference><Reference><Citation>Milder, F. J. et al. Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions. Proc. Natl Acad. Sci. USA 119, e2115379119 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35131851</ArticleId><ArticleId IdType="pmc">8833195</ArticleId><ArticleId IdType="doi">10.1073/pnas.2115379119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulp, D. W. et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat. Commun. 8, 1655 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29162799</ArticleId><ArticleId IdType="pmc">5698488</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-01549-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24068931</ArticleId><ArticleId IdType="pmc">3777863</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1003618</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachbagauer, R. et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines 2, 26 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29263881</ArticleId><ArticleId IdType="pmc">5627297</ArticleId><ArticleId IdType="doi">10.1038/s41541-017-0026-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Steichen, J. M. et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45, 483–496 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27617678</ArticleId><ArticleId IdType="pmc">5040827</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2016.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubrovskaya, V. et al. Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability. Immunity 51, 915–929.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31732167</ArticleId><ArticleId IdType="pmc">6891888</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2019.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker, L. M. &amp; Burton, D. R. Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray. Nat. Rev. Immunol. 18, 297–308 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29379211</ArticleId><ArticleId IdType="pmc">5918154</ArticleId><ArticleId IdType="doi">10.1038/nri.2017.148</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35962033</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00753-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, D. et al. Vaccine design via antigen reorientation. Nat. Chem. Biol. 20, 1012–1021 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38225471</ArticleId><ArticleId IdType="pmc">11247139</ArticleId><ArticleId IdType="doi">10.1038/s41589-023-01529-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh, C.-L. et al. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge. Nat. Commun. 15, 1553 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38378768</ArticleId><ArticleId IdType="pmc">10879192</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-45404-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang, W. et al. A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein. Cell Res. 32, 1068–1085 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36357786</ArticleId><ArticleId IdType="pmc">9648449</ArticleId><ArticleId IdType="doi">10.1038/s41422-022-00746-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson, D. P., Rynda-Apple, A., Harmsen, A. L., Harmsen, A. G. &amp; Douglas, T. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 7, 3036–3044 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23540530</ArticleId><ArticleId IdType="pmc">3773536</ArticleId><ArticleId IdType="doi">10.1021/nn4006544</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista, F. D., Iber, D. &amp; Neuberger, M. S. B cells acquire antigen from target cells after synapse formation. Nature 411, 489–494 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11373683</ArticleId><ArticleId IdType="doi">10.1038/35078099</ArticleId></ArticleIdList></Reference><Reference><Citation>Trombetta, E. S. &amp; Mellman, I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23, 975–1028 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15771591</ArticleId><ArticleId IdType="doi">10.1146/annurev.immunol.22.012703.104538</ArticleId></ArticleIdList></Reference><Reference><Citation>Bale, J. B. et al. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science 353, 389–394 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27463675</ArticleId><ArticleId IdType="pmc">5485857</ArticleId><ArticleId IdType="doi">10.1126/science.aaf8818</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420–1431.e17 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30849373</ArticleId><ArticleId IdType="pmc">6424820</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.01.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer, P. J. M. et al. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nat. Commun. 10, 4272 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31537780</ArticleId><ArticleId IdType="pmc">6753213</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12080-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623–628 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33762730</ArticleId><ArticleId IdType="pmc">8269962</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03365-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382.e17 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33160446</ArticleId><ArticleId IdType="pmc">7604136</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.10.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188–1200.e19 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33577765</ArticleId><ArticleId IdType="pmc">7834972</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.01.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432–5447.e16 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34619077</ArticleId><ArticleId IdType="pmc">8440233</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.09.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, M. D. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32669664</ArticleId><ArticleId IdType="doi">10.1038/s41565-020-0737-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries, C. N. et al. Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. Nat. Nanotechnol. 16, 1–14 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32807876</ArticleId><ArticleId IdType="doi">10.1038/s41565-020-0739-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders, K. O. et al. Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science 366, eaay7199 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31806786</ArticleId><ArticleId IdType="pmc">7168753</ArticleId><ArticleId IdType="doi">10.1126/science.aay7199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23698367</ArticleId><ArticleId IdType="pmc">8312026</ArticleId><ArticleId IdType="doi">10.1038/nature12202</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065–1070 (2015). This study demonstrates that HA stem immunogen displayed on self-assembling nanoparticles induces stem-specific antibodies and protects against diverse viral challenges in animal models.</Citation><ArticleIdList><ArticleId IdType="pubmed">26301691</ArticleId><ArticleId IdType="doi">10.1038/nm.3927</ArticleId></ArticleIdList></Reference><Reference><Citation>Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26303961</ArticleId><ArticleId IdType="doi">10.1126/science.aac7263</ArticleId></ArticleIdList></Reference><Reference><Citation>He, D. &amp; Marles-Wright, J. Ferritin family proteins and their use in bionanotechnology. New Biotechnol. 32, 651–657 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbt.2014.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo, M. et al. Rational design of an Epstein–Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090–1100 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26279189</ArticleId><ArticleId IdType="pmc">4757492</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.07.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362–372 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30742080</ArticleId><ArticleId IdType="pmc">6380945</ArticleId><ArticleId IdType="doi">10.1038/s41590-018-0305-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711–716 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23539181</ArticleId><ArticleId IdType="pmc">3689846</ArticleId><ArticleId IdType="doi">10.1126/science.1234150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders, R. W. &amp; Moore, J. P. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol. Rev. 275, 161–182 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28133806</ArticleId><ArticleId IdType="pmc">5299501</ArticleId><ArticleId IdType="doi">10.1111/imr.12481</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardine, J. G. et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349, 156–161 (2015). This work demonstrates that HIV immunogen eOD-GT8 binds with VRC01 bnAB precursor germline B cells at the CD4 binding site to prime bnAb response.</Citation><ArticleIdList><ArticleId IdType="pubmed">26089355</ArticleId><ArticleId IdType="pmc">4669217</ArticleId><ArticleId IdType="doi">10.1126/science.aac5894</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553–559 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33971664</ArticleId><ArticleId IdType="pmc">8528238</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03594-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371, 735–741 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33436524</ArticleId><ArticleId IdType="pmc">7928838</ArticleId><ArticleId IdType="doi">10.1126/science.abf6840</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576–1585 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7769295</ArticleId><ArticleId IdType="doi">10.1093/infdis/171.6.1576</ArticleId></ArticleIdList></Reference><Reference><Citation>RTS,S Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60721-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533–544 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38310910</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(23)02511-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft, J. C. et al. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Cell Rep. Med. 3, 100780 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36206752</ArticleId><ArticleId IdType="pmc">9589121</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2022.100780</ArticleId></ArticleIdList></Reference><Reference><Citation>Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383–391 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35115706</ArticleId><ArticleId IdType="pmc">10588819</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01660-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 15, eade4790 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37075129</ArticleId><ArticleId IdType="pmc">10619166</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.ade4790</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201–206 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24499818</ArticleId><ArticleId IdType="pmc">4260937</ArticleId><ArticleId IdType="doi">10.1038/nature12966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, T. T. et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl Acad. Sci. USA 107, 18979–18984 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20956293</ArticleId><ArticleId IdType="pmc">2973924</ArticleId><ArticleId IdType="doi">10.1073/pnas.1013387107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzarum, N., Wilson, I. A. &amp; Law, M. The neutralizing face of hepatitis C virus E2 envelope glycoprotein. Front. Immunol. 9, 1315 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29951061</ArticleId><ArticleId IdType="pmc">6008530</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.01315</ArticleId></ArticleIdList></Reference><Reference><Citation>Jelínková, L. et al. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model. NPJ Vaccines 7, 34 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35260593</ArticleId><ArticleId IdType="pmc">8904524</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00457-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. et al. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerg. Microbes Infect. 11, 2724–2734 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36287714</ArticleId><ArticleId IdType="pmc">9662039</ArticleId><ArticleId IdType="doi">10.1080/22221751.2022.2140608</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, F., Zai, X., Zhang, Z., Xu, J. &amp; Chen, W. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. NPJ Vaccines 7, 167 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36535982</ArticleId><ArticleId IdType="pmc">9761649</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00597-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect. Dis. 2, 361–376 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27627203</ArticleId><ArticleId IdType="pmc">7075522</ArticleId><ArticleId IdType="doi">10.1021/acsinfecdis.6b00006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosmann, T. R., McMichael, A. J., LeVert, A., McCauley, J. W. &amp; Almond, J. W. Opportunities and challenges for T cell-based influenza vaccines. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-024-01030-8 (2024).</Citation></Reference><Reference><Citation>Nathan, A. et al. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell 184, 4401–4413.e10 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34265281</ArticleId><ArticleId IdType="pmc">8241654</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.06.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Arieta, C. M. et al. The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. Cell 186, 2392–2409.e21 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37164012</ArticleId><ArticleId IdType="pmc">10099181</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2023.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai, W. et al. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants. Nat. Commun. 14, 2962 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37221158</ArticleId><ArticleId IdType="pmc">10204679</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-38751-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter, B. et al. A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta. Front. Immunol. 14, 1135815 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36969239</ArticleId><ArticleId IdType="pmc">10033589</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1135815</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasari, V. et al. Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice. Nat. Commun. 14, 4371 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37553346</ArticleId><ArticleId IdType="pmc">10409721</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39770-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks, S. G. &amp; Walker, B. D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406–416 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17892849</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2007.08.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyo, N. et al. Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA. Mol. Ther. Methods Clin. Dev. 12, 32–46 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30547051</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2018.10.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamley, I. W. Peptides for vaccine development. ACS Appl. Bio Mater. 5, 905–944 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35195008</ArticleId><ArticleId IdType="doi">10.1021/acsabm.1c01238</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary, N., Weissman, D. &amp; Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34433919</ArticleId><ArticleId IdType="doi">10.1038/s41573-021-00283-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom, K., van den Berg, F. &amp; Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117–129 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33093657</ArticleId><ArticleId IdType="doi">10.1038/s41434-020-00204-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu, D., Wu, Y. &amp; Lian, J. Circular RNA vaccine in disease prevention and treatment. Signal. Transduct. Target. Ther. 8, 341 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37691066</ArticleId><ArticleId IdType="doi">10.1038/s41392-023-01561-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoningo, J. S. &amp; Kinnear, E. Using plasmids as DNA vaccines for infectious diseases. Microbiol. Spectr. 10.1128/microbiolspec.plas-0028–2014 (2014).</Citation></Reference><Reference><Citation>Cunliffe, R. F. et al. Optimizing a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen. Discov. Immunol. 3, kyad030 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38567290</ArticleId><ArticleId IdType="doi">10.1093/discim/kyad030</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32756549</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2622-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, E. E. et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33053279</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, L. &amp; Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73–82 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33340022</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-00480-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, B. et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01082-6 (2023).</Citation></Reference><Reference><Citation>Zhang, P. et al. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med. 27, 2234–2245 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34887575</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01574-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu, Z. et al. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep. 38, 110514 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35294883</ArticleId><ArticleId IdType="pmc">8922439</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.110514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. A. G. et al. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell 186, 2380–2391.e9 (2023). This study utilizes mRNA encoding self-assembling enveloped VLPs that generate robust immune responses in a single injection.</Citation><ArticleIdList><ArticleId IdType="pubmed">37146611</ArticleId><ArticleId IdType="pmc">10121106</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2023.04.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyn, A. W. et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med. 15, eadg3540 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adg3540</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899–904 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36423275</ArticleId><ArticleId IdType="pmc">10790309</ArticleId><ArticleId IdType="doi">10.1126/science.abm0271</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science 373, 991–998 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34214046</ArticleId><ArticleId IdType="pmc">8899822</ArticleId><ArticleId IdType="doi">10.1126/science.abi4506</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart-Jones, G. B. E. et al. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Sci. Transl. Med. 15, eadf4100 (2024). This study demonstrates that mRNA vaccines encoding the N-terminal domain linked to the RBD of the SARS-CoV-2 spike protein provide comparable or superior protection to those encoding the full-length spike protein. Additionally, these domain-based vaccines exhibit better stability at refrigeration temperatures, making them more suitable for global distribution.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adf4100</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassini, P. et al. Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults. Hum. Vaccines Immunother. 19, 2190690 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2190690</ArticleId></ArticleIdList></Reference><Reference><Citation>Vostrosablin, N. et al. mRNAid, an open-source platform for therapeutic mRNA design and optimization strategies. NAR Genom. Bioinform. 6, lqae028 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38482061</ArticleId><ArticleId IdType="pmc">10935487</ArticleId><ArticleId IdType="doi">10.1093/nargab/lqae028</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, S. et al. CodonBERT large language models for mRNA design and optimization. Genome Res. 34, 1027–1035 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38951026</ArticleId><ArticleId IdType="doi">10.1101/gr.278870.123</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396–403 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37130545</ArticleId><ArticleId IdType="pmc">10499610</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06127-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35318324</ArticleId><ArticleId IdType="pmc">8940940</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-28776-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyn, A. W. et al. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol. Ther. Methods Clin. Dev. 22, 84–95 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34485597</ArticleId><ArticleId IdType="pmc">8390451</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2021.06.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam, H. H. et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc. Natl Acad. Sci. USA 113, E6639–E6648 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27702895</ArticleId><ArticleId IdType="pmc">5086995</ArticleId><ArticleId IdType="doi">10.1073/pnas.1606050113</ArticleId></ArticleIdList></Reference><Reference><Citation>Huysmans, H. et al. Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin. Mol. Ther. Nucleic Acids 17, 867–878 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31472371</ArticleId><ArticleId IdType="pmc">6722285</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2019.08.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda, Y. et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect. Dis. 24, 351–360 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38141632</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00650-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728–1744.e16 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35460644</ArticleId><ArticleId IdType="pmc">8971115</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.03.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft, R. A. et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol. Cell 74, 508–520.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30902547</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2019.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Aditham, A. et al. Chemically modified mocRNAs for highly efficient protein expression in mammalian cells. ACS Chem. Biol. 17, 3352–3366 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34995053</ArticleId><ArticleId IdType="doi">10.1021/acschembio.1c00569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262–272 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35851375</ArticleId><ArticleId IdType="doi">10.1038/s41587-022-01393-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, H. et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02174-7 (2024).</Citation></Reference><Reference><Citation>Khobragade, A. et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 399, 1313–1321 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35367003</ArticleId><ArticleId IdType="pmc">8970574</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)00151-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobiyama, K. &amp; Ishii, K. J. Making innate sense of mRNA vaccine adjuvanticity. Nat. Immunol. 23, 474–476 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35354958</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01168-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki, T., Kawai, T. &amp; Akira, S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol. Rev. 243, 61–73 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21884167</ArticleId><ArticleId IdType="pmc">7165622</ArticleId><ArticleId IdType="doi">10.1111/j.1600-065X.2011.01048.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddicoat, B. J. et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 349, 1115–1120 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26275108</ArticleId><ArticleId IdType="pmc">5444807</ArticleId><ArticleId IdType="doi">10.1126/science.aac7049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung, V. et al. 5’-Triphosphate RNA is the ligand for RIG-I. Science 314, 994–997 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17038590</ArticleId><ArticleId IdType="doi">10.1126/science.1132505</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543–555 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35288714</ArticleId><ArticleId IdType="pmc">8989677</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01163-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022). This study demonstrates that the ionizable lipid component of mRNA vaccines drives IL-1 pathway activation, TLR signalling and cytokine release, with these effects being more pronounced in human leukocytes than in their murine counterparts.</Citation><ArticleIdList><ArticleId IdType="pubmed">35332327</ArticleId><ArticleId IdType="doi">10.1038/s41590-022-01160-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello, C. A. Cytokines as endogenous pyrogens. J. Infect. Dis. 179, S294–S304 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10081499</ArticleId><ArticleId IdType="doi">10.1086/513856</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathinam, V. A. K., Vanaja, S. K. &amp; Fitzgerald, K. A. Regulation of inflammasome signaling. Nat. Immunol. 13, 333–342 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22430786</ArticleId><ArticleId IdType="pmc">3523703</ArticleId><ArticleId IdType="doi">10.1038/ni.2237</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, A. H. &amp; Schroder, K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J. Exp. Med. 217, e20190314 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">7037238</ArticleId><ArticleId IdType="doi">10.1084/jem.20190314</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó, K., Buckstein, M., Ni, H. &amp; Weissman, D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16111635</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18797453</ArticleId><ArticleId IdType="doi">10.1038/mt.2008.200</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326–1335 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28273716</ArticleId><ArticleId IdType="doi">10.1021/acs.nanolett.6b03329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Z. et al. Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice. Mol. Ther. Nucleic Acids 34, 102045 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37876532</ArticleId><ArticleId IdType="pmc">10591005</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2023.102045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebre, M. S. et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature 601, 410–414 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34794169</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-04231-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulroney, T. E. et al. N<sup>1</sup>-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature 625, 189–194 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38057663</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06800-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinman, D. M., Yamshchikov, G. &amp; Ishigatsubo, Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158, 3635–3639 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9103425</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.158.8.3635</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Sandoval, A. &amp; Ertl, H. C. J. CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol. Ther. 9, 249–261 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14759809</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2003.11.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsui, M. et al. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J. Gene Med. 11, 435–443 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19291673</ArticleId><ArticleId IdType="doi">10.1002/jgm.1317</ArticleId></ArticleIdList></Reference><Reference><Citation>Suschak, J. J., Wang, S., Fitzgerald, K. A. &amp; Lu, S. A cGAS-independent STING/IRF7 pathway mediates the immunogenicity of DNA vaccines. J. Immunol. 196, 310–316 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26590319</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1501836</ArticleId></ArticleIdList></Reference><Reference><Citation>Suschak, J. J., Wang, S., Fitzgerald, K. A. &amp; Lu, S. Identification of Aim2 as a sensor for DNA vaccines. J. Immunol. 194, 630–636 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25488991</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1402530</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen, A. et al. Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. Cancer Immunol. Immunother. 67, 627–638 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29330557</ArticleId><ArticleId IdType="pmc">5860099</ArticleId><ArticleId IdType="doi">10.1007/s00262-017-2111-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Suschak, J. J. et al. Nanoplasmid vectors co-expressing innate immune agonists enhance DNA vaccines for Venezuelan equine encephalitis virus and Ebola virus. Mol. Ther. Methods Clin. Dev. 17, 810–821 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32296729</ArticleId><ArticleId IdType="pmc">7158766</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2020.04.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Didierlaurent, A. M. et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J. Immunol. 193, 1920–1930 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25024381</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1400948</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812–1823 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21215831</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2010.12.090</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, F. et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med. 9, eaal2094 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28592561</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aal2094</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyer, T. J. et al. Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat. Med. 26, 430–440 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32066977</ArticleId><ArticleId IdType="pmc">7069805</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0753-3</ArticleId></ArticleIdList></Reference><Reference><Citation>He, P., Zou, Y. &amp; Hu, Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum. Vaccines Immunother. 11, 477–488 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2014.1004026</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyer, T. J., Zmolek, A. C. &amp; Irvine, D. J. Beyond antigens and adjuvants: formulating future vaccines. J. Clin. Investig. 126, 799–808 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26928033</ArticleId><ArticleId IdType="pmc">4767337</ArticleId><ArticleId IdType="doi">10.1172/JCI81083</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed, S. G., Orr, M. T. &amp; Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597–1608 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24309663</ArticleId><ArticleId IdType="doi">10.1038/nm.3409</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran, B., S. Arunachalam, P. &amp; O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33824489</ArticleId><ArticleId IdType="pmc">8023785</ArticleId><ArticleId IdType="doi">10.1038/s41573-021-00163-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody, M. A. et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J. Virol. 88, 3329–3339 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24390332</ArticleId><ArticleId IdType="pmc">3957956</ArticleId><ArticleId IdType="doi">10.1128/JVI.03309-13</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper, C. &amp; Mackie, D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV<sup>TM</sup> safety and efficacy. Expert Rev. Vaccines 10, 417–427 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21506639</ArticleId><ArticleId IdType="doi">10.1586/erv.10.162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, B. et al. Selective utilization of toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34, 375–384 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21353603</ArticleId><ArticleId IdType="pmc">3064721</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2011.01.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Francica, J. R. et al. Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nat. Commun. 6, 6565 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25858157</ArticleId><ArticleId IdType="doi">10.1038/ncomms7565</ArticleId></ArticleIdList></Reference><Reference><Citation>Stertman, L. et al. The Matrix-M<sup>TM</sup> adjuvant: a critical component of vaccines for the 21<sup>st</sup> century. Hum. Vaccines Immunother. 19, 2189885 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2189885</ArticleId></ArticleIdList></Reference><Reference><Citation>Counoupas, C. et al. Delta inulin-based adjuvants promote the generation of polyfunctional CD4<sup>+</sup> T cell responses and protection against Mycobacterium tuberculosis infection. Sci. Rep. 7, 8582 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28819247</ArticleId><ArticleId IdType="pmc">5561132</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-09119-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Casella, C. R. &amp; Mitchell, T. C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65, 3231–3240 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18668203</ArticleId><ArticleId IdType="pmc">2647720</ArticleId><ArticleId IdType="doi">10.1007/s00018-008-8228-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Baay, M., Bollaerts, K. &amp; Verstraeten, T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults. Vaccine 36, 4207–4214 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29885773</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2018.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, E. et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346, f794 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23444425</ArticleId><ArticleId IdType="doi">10.1136/bmj.f794</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24531764</ArticleId><ArticleId IdType="pmc">4069155</ArticleId><ArticleId IdType="doi">10.1038/nature12978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushach, I. et al. Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection. Mol. Ther. Nucleic Acids 27, 1103–1115 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35228903</ArticleId><ArticleId IdType="pmc">8857595</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2022.01.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, Q. et al. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nat. Mater. 22, 380–390 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36717665</ArticleId><ArticleId IdType="pmc">9981462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitragotri, S., Burke, P. A. &amp; Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655–672 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25103255</ArticleId><ArticleId IdType="pmc">4455970</ArticleId><ArticleId IdType="doi">10.1038/nrd4363</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevaskis, N. L., Kaminskas, L. M. &amp; Porter, C. J. H. From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 14, 781–803 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26471369</ArticleId><ArticleId IdType="doi">10.1038/nrd4608</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. &amp; Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35534554</ArticleId><ArticleId IdType="doi">10.1038/s41587-022-01294-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, W. et al. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Adv. Healthc. Mater. 10, 2001812 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33458958</ArticleId><ArticleId IdType="pmc">7995055</ArticleId><ArticleId IdType="doi">10.1002/adhm.202001812</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines 9, 65 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33478109</ArticleId><ArticleId IdType="pmc">7836001</ArticleId><ArticleId IdType="doi">10.3390/vaccines9010065</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, D. M., Simon, J. K. &amp; Baker, J. R. Jr Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13, 592–605 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23883969</ArticleId><ArticleId IdType="pmc">7097370</ArticleId><ArticleId IdType="doi">10.1038/nri3488</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine, D. J., Hanson, M. C., Rakhra, K. &amp; Tokatlian, T. Synthetic nanoparticles for vaccines and immunotherapy. Chem. Rev. 115, 11109–11146 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26154342</ArticleId><ArticleId IdType="pmc">4688911</ArticleId><ArticleId IdType="doi">10.1021/acs.chemrev.5b00109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibbitt, M. W., Dahlman, J. E. &amp; Langer, R. Emerging frontiers in drug delivery. J. Am. Chem. Soc. 138, 704–717 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26741786</ArticleId><ArticleId IdType="doi">10.1021/jacs.5b09974</ArticleId></ArticleIdList></Reference><Reference><Citation>Pati, R., Shevtsov, M. &amp; Sonawane, A. Nanoparticle vaccines against infectious diseases. Front. Immunol. 9, 2224 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30337923</ArticleId><ArticleId IdType="pmc">6180194</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.02224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, A., Andresen, J. L., Manan, R. S. &amp; Langer, R. Nucleic acid delivery for therapeutic applications. Adv. Drug. Deliv. Rev. 178, 113834 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34492233</ArticleId><ArticleId IdType="doi">10.1016/j.addr.2021.113834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong, R. et al. Hydrogels for RNA delivery. Nat. Mater. 22, 818–831 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36941391</ArticleId><ArticleId IdType="pmc">10330049</ArticleId><ArticleId IdType="doi">10.1038/s41563-023-01472-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirtane, A. R. et al. Nanotechnology approaches for global infectious diseases. Nat. Nanotechnol. 16, 369–384 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33753915</ArticleId><ArticleId IdType="doi">10.1038/s41565-021-00866-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauthner, M. et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. Immunity 46, 1073–1088.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28636956</ArticleId><ArticleId IdType="pmc">5483234</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2017.05.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Di, J. et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm. Res. 39, 105–114 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35080707</ArticleId><ArticleId IdType="pmc">8791091</ArticleId><ArticleId IdType="doi">10.1007/s11095-022-03166-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett, K. J. et al. mRNA vaccine trafficking and resulting protein expression after intramuscular administration. Mol. Ther. Nucleic Acids 35, 102083 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38161733</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2023.102083</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 25, 2635–2647 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28958578</ArticleId><ArticleId IdType="pmc">5768558</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.08.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30785039</ArticleId><ArticleId IdType="pmc">6383180</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2019.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope, M. et al. Lipid nanoparticle formulations. WIPO patent WO-2018081480-A1 (2018).</Citation></Reference><Reference><Citation>Lu, X., Li, Z., Song, H. &amp; Ying, B. Quadrivalent mRNA vaccines for influenza viruses. WIPO patent WO2023125889A1 (2023).</Citation></Reference><Reference><Citation>Zhang, N.-N. et al. A thermostable mRNA vaccine against COVID-19. Cell 182, 1271–1283.e16 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32795413</ArticleId><ArticleId IdType="pmc">7377714</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.07.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajappan, K. et al. Property-driven design and development of lipids for efficient delivery of siRNA. J. Med. Chem. 63, 12992–13012 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33119286</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01407</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam, K. et al. Unsaturated, trialkyl ionizable lipids are versatile lipid-nanoparticle components for therapeutic and vaccine applications. Adv. Mater. 35, e2209624 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36680477</ArticleId><ArticleId IdType="doi">10.1002/adma.202209624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatechompol, S. et al. Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial. Nat. Microbiol. 7, 1987–1995 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36376393</ArticleId><ArticleId IdType="doi">10.1038/s41564-022-01271-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Broudic, K. et al. Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery. Toxicol. Appl. Pharmacol. 451, 116143 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35843341</ArticleId><ArticleId IdType="doi">10.1016/j.taap.2022.116143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalnin, K. V. et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 6, 61 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33875658</ArticleId><ArticleId IdType="pmc">8055913</ArticleId><ArticleId IdType="doi">10.1038/s41541-021-00324-5</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRosa, F., Karve, S. &amp; Heartlein, M. Stereochemically enriched compositions for delivery of nucleic acids. US patent US20190185435A1 (2019).</Citation></Reference><Reference><Citation>Koizumi, M., Onishi, Y., Niwa, T., Tamura, M. &amp; Kasuya, Y. Novel lipid. WIPO patent WO2015005253A1 (2015).</Citation></Reference><Reference><Citation>Nussbaum, J. et al. Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine 41, 6488–6501 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37777449</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.05.062</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan, R., Clancy, E. K., Lewis, J., Justo De Antueno, R. &amp; Nesbitt R.-L. Recombinant polypeptides for membrane fusion and uses thereof. US patent 10,227,386B2 (2019).</Citation></Reference><Reference><Citation>Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M. &amp; Da Silva, F. T. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines 4, 39 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31583123</ArticleId><ArticleId IdType="pmc">6760227</ArticleId><ArticleId IdType="doi">10.1038/s41541-019-0132-6</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lombaerde, E. Combinatorial screening of biscarbamate ionizable lipids identifies a low reactogenicity lipid for lipid nanoparticle mRNA delivery. Adv. Funct. Mater. 34, 2310623 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.202310623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, B. et al. Disruptions in endocytic traffic contribute to the activation of the NLRP3 inflammasome. Sci. Signal. 16, eabm7134 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36809026</ArticleId><ArticleId IdType="doi">10.1126/scisignal.abm7134</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurston, T. L. M., Wandel, M. P., von Muhlinen, N., Foeglein, Á. &amp; Randow, F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 482, 414–418 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22246324</ArticleId><ArticleId IdType="pmc">3343631</ArticleId><ArticleId IdType="doi">10.1038/nature10744</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm, C. K. et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 13, 737–743 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22706339</ArticleId><ArticleId IdType="pmc">3411909</ArticleId><ArticleId IdType="doi">10.1038/ni.2350</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021). This study demonstrates that LNPs can function as adjuvants by stimulating IL-6 production, thereby enhancing antigen-specific follicular T-helper and germinal centre B cell responses and amplifying immune responses when used with protein subunit vaccines.</Citation><ArticleIdList><ArticleId IdType="pubmed">34852217</ArticleId><ArticleId IdType="pmc">8566475</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36539526</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00825-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31570898</ArticleId><ArticleId IdType="doi">10.1038/s41587-019-0247-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2. Nano Lett. 23, 2593–2600 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36942873</ArticleId><ArticleId IdType="doi">10.1021/acs.nanolett.2c04883</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105–1114 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37365276</ArticleId><ArticleId IdType="doi">10.1038/s41565-023-01404-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, J. et al. Nanomaterials-mediated co-stimulation of toll-like receptors and CD40 for antitumor immunity. Adv. Mater. 34, e2207486 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36121735</ArticleId><ArticleId IdType="doi">10.1002/adma.202207486</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly, G., Laczka, O. &amp; Gantier, M. Methods for the treatment of inflammation associated with infection. US Patent US11541030B2 (2023).</Citation></Reference><Reference><Citation>Tong, A.-J. et al. Nucleotide modifications enable rational design of TLR7-selective ligands by blocking RNase cleavage. J. Exp. Med. 221, e20230341 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38095631</ArticleId><ArticleId IdType="doi">10.1084/jem.20230341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan, T. et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc. Natl Acad. Sci. USA 104, 13750–13755 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17698957</ArticleId><ArticleId IdType="doi">10.1073/pnas.0706059104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla, E. R. et al. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cell. Immunol. 270, 126–134 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21570062</ArticleId><ArticleId IdType="doi">10.1016/j.cellimm.2011.03.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirai, S. et al. Lipid nanoparticles potentiate CpG-oligodeoxynucleotide-based vaccine for influenza virus. Front. Immunol. 10, 3018 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31998305</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.03018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastenmüller, W., Kastenmüller, K., Kurts, C. &amp; Seder, R. A. Dendritic cell-targeted vaccines — hope or hype? Nat. Rev. Immunol. 14, 705–711 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25190285</ArticleId><ArticleId IdType="doi">10.1038/nri3727</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, X. et al. Simultaneous dendritic cells targeting and effective endosomal escape enhance sialic acid-modified mRNA vaccine efficacy and reduce side effects. J. Control. Release 364, 529–545 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37949317</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2023.11.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan, J. et al. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses. mBio 15, e0177523 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38078742</ArticleId><ArticleId IdType="doi">10.1128/mbio.01775-23</ArticleId></ArticleIdList></Reference><Reference><Citation>Talukder, P., Chahal, J., Huang, J. &amp; Ruping, K. Carriers for efficient nucleic acid delivery. WIPO patent WO2021207020A1 (2021).</Citation></Reference><Reference><Citation>Künzli, M. et al. Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells. Sci. Immunol. 7, eadd3075 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36459542</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.add3075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34841223</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2021.103479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibowo, D. et al. Polymeric nanoparticle vaccines to combat emerging and pandemic threats. Biomaterials 268, 120597 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33360074</ArticleId><ArticleId IdType="doi">10.1016/j.biomaterials.2020.120597</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel, A. B. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446–455 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29275847</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2017.11.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney, A. K., Yilmaz, G., McKay, P. F., Becer, C. R. &amp; Shattock, R. J. One size does not fit all: the effect of chain length and charge density of poly(ethylene imine) based copolymers on delivery of pDNA, mRNA, and RepRNA polyplexes. Biomacromolecules 19, 2870–2879 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29698602</ArticleId><ArticleId IdType="doi">10.1021/acs.biomac.8b00429</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, M. et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J. Control. Release 228, 9–19 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26941035</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2016.02.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney, A. K. et al. Big is beautiful: enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer. ACS Nano 14, 5711–5727 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32267667</ArticleId><ArticleId IdType="pmc">7304921</ArticleId><ArticleId IdType="doi">10.1021/acsnano.0c00326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133–42 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27382155</ArticleId><ArticleId IdType="pmc">4961123</ArticleId><ArticleId IdType="doi">10.1073/pnas.1600299113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28325910</ArticleId><ArticleId IdType="pmc">5427874</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-00193-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J. et al. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat. Mater. 11, 82–90 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmat3187</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberi, A. et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci. Transl. Med. 15, eabq0603 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abq0603</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaya, L. et al. Circular RNA vaccine induces potent T cell responses. Proc. Natl Acad. Sci. USA 120, e2302191120 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37155869</ArticleId><ArticleId IdType="pmc">10193964</ArticleId><ArticleId IdType="doi">10.1073/pnas.2302191120</ArticleId></ArticleIdList></Reference><Reference><Citation>Haabeth, O. A. W. et al. An mRNA SARS-CoV-2 vaccine employing charge-altering releasable transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory. ACS Cent. Sci. 7, 1191–1204 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34341771</ArticleId><ArticleId IdType="pmc">8265720</ArticleId><ArticleId IdType="doi">10.1021/acscentsci.1c00361</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543–547 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21350488</ArticleId><ArticleId IdType="pmc">3057367</ArticleId><ArticleId IdType="doi">10.1038/nature09737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasturi, S. P. et al. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. 5, eabb1025 (2020). This study demonstrates that 3M-052 enhances the response to an HIV-1 Env protein vaccine in rhesus macaques, leading to long-lasting antibody responses detectable a year later. This effect is attributed to the ability of 3M-052 to sustain long-lived plasma cell responses.</Citation><ArticleIdList><ArticleId IdType="pubmed">32561559</ArticleId><ArticleId IdType="pmc">8109745</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.abb1025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal, S. et al. Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. J. Control. Release 247, 194–205 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28057521</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2016.12.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. Rationally designed self-assembling nanoparticles to overcome mucus and epithelium transport barriers for oral vaccines against Helicobacter pylori. Adv. Funct. Mater. 28, 1802675 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.201802675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, H. et al. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2. Signal Transduct. Target. Ther. 5, 291 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33311439</ArticleId><ArticleId IdType="pmc">7729145</ArticleId><ArticleId IdType="doi">10.1038/s41392-020-00434-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, D. S. et al. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nat. Mater. 18, 175–185 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30643235</ArticleId><ArticleId IdType="doi">10.1038/s41563-018-0256-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray, L. T. et al. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. Biomaterials 278, 121159 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34634664</ArticleId><ArticleId IdType="pmc">8482845</ArticleId><ArticleId IdType="doi">10.1016/j.biomaterials.2021.121159</ArticleId></ArticleIdList></Reference><Reference><Citation>Liong, C. S. et al. Enhanced humoral immune response by high density TLR agonist presentation on hyperbranched polymers. Adv. Ther. 4, 2000081 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.202000081</ArticleId></ArticleIdList></Reference><Reference><Citation>Atalis, A. et al. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine. J. Control. Release 347, 476–488 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35577151</ArticleId><ArticleId IdType="pmc">9121740</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2022.05.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight, F. C. et al. Mucosal immunization with a pH-responsive nanoparticle vaccine induces protective CD8<sup>+</sup> lung-resident memory T cells. ACS Nano 13, 10939–10960 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31553872</ArticleId><ArticleId IdType="pmc">6832804</ArticleId><ArticleId IdType="doi">10.1021/acsnano.9b00326</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, Y. et al. Rational development of a polysaccharide–protein-conjugated nanoparticle vaccine against SARS-CoV-2 variants and Streptococcus pneumoniae. Adv. Mater. 34, e2200443 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35332581</ArticleId><ArticleId IdType="doi">10.1002/adma.202200443</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneziano, R. et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat. Nanotechnol. 15, 716–723 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32601450</ArticleId><ArticleId IdType="pmc">7415668</ArticleId><ArticleId IdType="doi">10.1038/s41565-020-0719-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548–563.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32857950</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2020.08.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Murillo, P. et al. Particulate array of well-ordered HIV clade C Env trimers elicits neutralizing antibodies that display a unique V2 cap approach. Immunity 46, 804–817.e7 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28514687</ArticleId><ArticleId IdType="pmc">5528178</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2017.04.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries, L. F., Smith, G. E. &amp; Glenn, G. M. A recombinant viruslike particle influenza A (H7N9) vaccine. N. Engl. J. Med. 369, 2564–2566 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24224560</ArticleId><ArticleId IdType="doi">10.1056/NEJMc1313186</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. V. et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine 33, 2152–2158 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25772674</ArticleId><ArticleId IdType="pmc">5805130</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer, F. &amp; Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14, 167–182 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25722244</ArticleId><ArticleId IdType="doi">10.1038/nrd4529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, B. J. et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat. Med. 27, 1071–1078 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34007070</ArticleId><ArticleId IdType="pmc">8205852</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01370-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, W.-C. et al. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes. Nat. Nanotechnol. 13, 1174–1181 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30297818</ArticleId><ArticleId IdType="pmc">6286227</ArticleId><ArticleId IdType="doi">10.1038/s41565-018-0271-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791–805 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35788687</ArticleId><ArticleId IdType="pmc">10782831</ArticleId><ArticleId IdType="doi">10.1038/s41551-022-00902-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Popowski, K. D. et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 5, 2960–2974 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35847197</ArticleId><ArticleId IdType="pmc">9272513</ArticleId><ArticleId IdType="doi">10.1016/j.matt.2022.06.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Weyant, K. B. et al. A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens. Nat. Commun. 14, 464 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36709333</ArticleId><ArticleId IdType="pmc">9883832</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-36101-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazli, S. et al. Contralateral second dose improves antibody responses to a two-dose mRNA vaccination regimen. J. Clin. Investig. 34, e176411 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI176411</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. Multiplexed CRISPR/CAS9‐mediated engineering of pre‐clinical mouse models bearing native human B cell receptors. EMBO J. 40, e105926 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33258500</ArticleId><ArticleId IdType="pmc">7809789</ArticleId><ArticleId IdType="doi">10.15252/embj.2020105926</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehm, M. A., Wiles, M. V., Greiner, D. L. &amp; Shultz, L. D. Generation of improved humanized mouse models for human infectious diseases. J. Immunol. Methods 410, 3–17 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24607601</ArticleId><ArticleId IdType="pmc">4155027</ArticleId><ArticleId IdType="doi">10.1016/j.jim.2014.02.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Higbee, R. G. et al. An immunologic model for rapid vaccine assessment — a clinical trial in a test tube. Altern. Lab. Anim. 37, 19–27 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19807200</ArticleId><ArticleId IdType="doi">10.1177/026119290903701S05</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainho-Tomko, J. N. et al. Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle. NPJ Vaccines 7, 74 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35773301</ArticleId><ArticleId IdType="pmc">9244890</ArticleId><ArticleId IdType="doi">10.1038/s41541-022-00487-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Massare, M. J. et al. Combination respiratory vaccine containing recombinant SARS-CoV-2 spike and quadrivalent seasonal influenza hemagglutinin nanoparticles with matrix-M adjuvant. Preprint at bioRxiv https://doi.org/10.1101/2021.05.05.442782 (2021).</Citation></Reference><Reference><Citation>Prompetchara, E. et al. Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. Nat. Commun. 14, 2309 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37085495</ArticleId><ArticleId IdType="pmc">10120480</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-37795-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, J. Y. et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomised, placebo-controlled, observer-blinded phase 1/2 trial. EClinicalMedicine 51, 101569 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35879941</ArticleId><ArticleId IdType="pmc">9304916</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2022.101569</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraf, A. et al. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Nat. Med. 30, 1363–1372 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38637636</ArticleId><ArticleId IdType="pmc">11108772</ArticleId><ArticleId IdType="doi">10.1038/s41591-024-02955-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, J.-H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33446655</ArticleId><ArticleId IdType="pmc">7809486</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-20653-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, I. T. et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37336877</ArticleId><ArticleId IdType="pmc">10279702</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39376-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, B. J., Séguin, A., Couillard, J., Trépanier, S. &amp; Landry, N. Phase III: randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18–49 years of age. Vaccine 39, 1528–1533 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33581920</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2021.01.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde, V. et al. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infect. Dis. 22, 73–84 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34563277</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00192-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Treanor, J. et al. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Vaccine 38, 5842–5850 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32563606</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2020.06.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, G. L. et al. Effect of a chikungunya virus–like particle vaccine on safety and tolerability outcomes: a randomized clinical trial. JAMA 323, 1369–1377 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32286643</ArticleId><ArticleId IdType="pmc">7156994</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.2477</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, S. R. et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect. Dis. 22, 1343–1355 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35709798</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00226-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Datoo, M. S. et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years’ follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect. Dis. 22, 1728–1736 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36087586</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(22)00442-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard, J. A., Fries, L. F., Cho, I., Chen, J. &amp; Laxminarayan, R. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proc. Natl Acad. Sci. USA 119, e2112410119 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35286196</ArticleId><ArticleId IdType="pmc">8944586</ArticleId><ArticleId IdType="doi">10.1073/pnas.2112410119</ArticleId></ArticleIdList></Reference><Reference><Citation>Falloon, J. et al. An adjuvanted, postfusion F protein–based vaccine did not prevent respiratory syncytial virus illness in older adults. J. Infect. Dis. 216, 1362–1370 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29029260</ArticleId><ArticleId IdType="pmc">5853767</ArticleId><ArticleId IdType="doi">10.1093/infdis/jix503</ArticleId></ArticleIdList></Reference><Reference><Citation>Fly, J. H., Eiland, L. S. &amp; Stultz, J. S. Nirsevimab: expansion of respiratory syncytial virus prevention options in neonates, infants, and at-risk young children. Ann. Pharmacother. https://doi.org/10.1177/10600280241243357 (2024).</Citation></Reference><Reference><Citation>Bollman, B. et al. An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection. NPJ Vaccines 8, 58 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37080988</ArticleId><ArticleId IdType="pmc">10119314</ArticleId><ArticleId IdType="doi">10.1038/s41541-023-00656-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin, S. A. Updates on immunologic correlates of vaccine-induced protection. Vaccine 38, 2250–2257 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31767462</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2019.10.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Boes, M. Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. 37, 1141–1149 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11451419</ArticleId><ArticleId IdType="doi">10.1016/S0161-5890(01)00025-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton, D. R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706–713 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12209139</ArticleId><ArticleId IdType="doi">10.1038/nri891</ArticleId></ArticleIdList></Reference><Reference><Citation>Corthésy, B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front. Immunol. 4, 185 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23874333</ArticleId><ArticleId IdType="pmc">3709412</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2013.00185</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogan, I. et al. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 10, 1292–1299 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19855380</ArticleId><ArticleId IdType="doi">10.1038/ni.1814</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesters, B. A., Myers, R. C. &amp; Carroll, M. C. Follicular dendritic cells: dynamic antigen libraries. Nat. Rev. Immunol. 14, 495–504 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24948364</ArticleId><ArticleId IdType="doi">10.1038/nri3689</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty, S. T. Follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132–1148 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31117010</ArticleId><ArticleId IdType="pmc">6532429</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2019.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape, K. A., Catron, D. M., Itano, A. A. &amp; Jenkins, M. K. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 26, 491–502 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17379546</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2007.02.011</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva, N. S. &amp; Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25656706</ArticleId><ArticleId IdType="pmc">4399774</ArticleId><ArticleId IdType="doi">10.1038/nri3804</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, F. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153, 126–138 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23540694</ArticleId><ArticleId IdType="pmc">3792590</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.03.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021). This study demonstrates that mRNA vaccines, such as BNT162b2, induce a strong but transient plasmablast response and a sustained germinal centre B cell response in lymph nodes, contributing to long-lasting humoral immunity. Additionally, cross-reactive B cell clones exhibit higher levels of somatic hypermutation, suggesting a memory B cell origin.</Citation><ArticleIdList><ArticleId IdType="pubmed">34182569</ArticleId><ArticleId IdType="pmc">8935394</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03738-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto, F., Lanzavecchia, A., Araki, K. &amp; Ahmed, R. From vaccines to memory and back. Immunity 33, 451–463 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21029957</ArticleId><ArticleId IdType="pmc">3760154</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2010.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya, M., Kwak, K. &amp; Pierce, S. K. B cell memory: building two walls of protection against pathogens. Nat. Rev. Immunol. 20, 229–238 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31836872</ArticleId><ArticleId IdType="doi">10.1038/s41577-019-0244-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Batista, F. D. &amp; Harwood, N. E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9, 15–27 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19079135</ArticleId><ArticleId IdType="doi">10.1038/nri2454</ArticleId></ArticleIdList></Reference><Reference><Citation>Akondy, R. S. et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8<sup>+</sup> T cell response. J. Immunol. 183, 7919–7930 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19933869</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.0803903</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam, P. S. et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. 26, 932–940 (2020). This study shows that vaccines inducing a strong antigen-specific CD8<sup>+</sup> memory T cell response lower the threshold of neutralizing antibodies to elicit protection against the infection, indicating a potential synergy between T<sub>RM</sub> cells and antibody responses.</Citation><ArticleIdList><ArticleId IdType="pubmed">32393800</ArticleId><ArticleId IdType="pmc">7303014</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0858-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, J. D. et al. Human effector and memory CD8<sup>+</sup> T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710–722 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18468462</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2008.02.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickhoff, S. et al. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell 162, 1322–1337 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26296422</ArticleId><ArticleId IdType="pmc">4567961</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi, H., Kastenmüller, W. &amp; Germain, R. N. Spatiotemporal basis of innate and adaptive immunity in secondary lymphoid tissue. Annu. Rev. Cell Dev. Biol. 30, 141–167 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25150013</ArticleId><ArticleId IdType="doi">10.1146/annurev-cellbio-100913-013254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, J. T., Wherry, E. J. &amp; Goldrath, A. W. Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 15, 1104–1115 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25396352</ArticleId><ArticleId IdType="pmc">4386685</ArticleId><ArticleId IdType="doi">10.1038/ni.3031</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach, C. et al. One naive T cell, multiple fates in CD8<sup>+</sup> T cell differentiation. J. Exp. Med. 207, 1235–1246 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20479114</ArticleId><ArticleId IdType="pmc">2882844</ArticleId><ArticleId IdType="doi">10.1084/jem.20091175</ArticleId></ArticleIdList></Reference><Reference><Citation>Stemberger, C. et al. A single naive CD8<sup>+</sup> T cell precursor can develop into diverse effector and memory subsets. Immunity 27, 985–997 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18082432</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2007.10.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhardt, T. et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10, 524–530 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19305395</ArticleId><ArticleId IdType="doi">10.1038/ni.1718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenkel, J. M. et al. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346, 98–101 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25170049</ArticleId><ArticleId IdType="pmc">4449618</ArticleId><ArticleId IdType="doi">10.1126/science.1254536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech, S. M., Wherry, E. J. &amp; Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251–262 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12001996</ArticleId><ArticleId IdType="doi">10.1038/nri778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, T. et al. Lung-resident memory CD8 T cells (T<sub>RM</sub>) are indispensable for optimal cross-protection against pulmonary virus infection. J. Leukoc. Biol. 95, 215–224 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24006506</ArticleId><ArticleId IdType="pmc">3896663</ArticleId><ArticleId IdType="doi">10.1189/jlb.0313180</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzolla, A. et al. Resident memory CD8<sup>+</sup> T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Sci. Immunol. 2, eaam6970 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28783656</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.aam6970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, L., Chong, M. M. W. &amp; Littman, D. R. Plasticity of CD4<sup>+</sup> T cell lineage differentiation. Immunity 30, 646–655 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19464987</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2009.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournazos, S., Gupta, A. &amp; Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633–643 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32782358</ArticleId><ArticleId IdType="pmc">7418887</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-00410-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. K. et al. B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells. J. Exp. Med. 208, 1377–1388 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21708925</ArticleId><ArticleId IdType="pmc">3135363</ArticleId><ArticleId IdType="doi">10.1084/jem.20102065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani, A., Dinarello, C. A., Molgora, M. &amp; Garlanda, C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity 50, 778–795 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30995499</ArticleId><ArticleId IdType="pmc">7174020</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2019.03.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Saper, C. B., Romanovsky, A. A. &amp; Scammell, T. E. Neural circuitry engaged by prostaglandins during the sickness syndrome. Nat. Neurosci. 15, 1088–1095 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22837039</ArticleId><ArticleId IdType="pmc">3748818</ArticleId><ArticleId IdType="doi">10.1038/nn.3159</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot, S., Foster, S. L. &amp; Woolf, C. J. Neuroimmunity: physiology and pathology. Annu. Rev. Immunol. 34, 421–447 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26907213</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-041015-055340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobolev, O. et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat. Immunol. 17, 204–213 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26726811</ArticleId><ArticleId IdType="pmc">6485475</ArticleId><ArticleId IdType="doi">10.1038/ni.3328</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki, A. &amp; Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 20, 339–341 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32317716</ArticleId><ArticleId IdType="pmc">7187142</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-0321-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvin, A. M. et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584, 353–363 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32659783</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2538-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29097492</ArticleId><ArticleId IdType="pmc">5858873</ArticleId><ArticleId IdType="doi">10.1126/science.aan6836</ArticleId></ArticleIdList></Reference><Reference><Citation>Houser, K. V. et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 13, e1006565 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28817732</ArticleId><ArticleId IdType="pmc">5574614</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1006565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin, J., Magoffin, R. L., Shearer, L. A. N. N., Schieble, J. H. &amp; Lennette, E. H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population1. Am. J. Epidemiol. 89, 449–463 (1969).</Citation><ArticleIdList><ArticleId IdType="pubmed">4305200</ArticleId><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a120957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruckwardt, T. J., Morabito, K. M. &amp; Graham, B. S. Immunological lessons from respiratory syncytial virus vaccine development. Immunity 51, 429–442 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31533056</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2019.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, B. S. et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151, 2032–2040 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8345194</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.151.4.2032</ArticleId></ArticleIdList></Reference><Reference><Citation>Openshaw, P. J. M., Chiu, C., Culley, F. J. &amp; Johansson, C. Protective and harmful immunity to RSV infection. Annu. Rev. Immunol. 35, 501–532 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28226227</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-051116-052206</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabrouk, M. T. et al. Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice. Sci. Adv. 7, eabj1476 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abj1476</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu, H. et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol. Ther. 30, 1941–1951 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35131437</ArticleId><ArticleId IdType="pmc">8815268</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai, L. et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 9, 9 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36683074</ArticleId><ArticleId IdType="pmc">9868121</ArticleId><ArticleId IdType="doi">10.1038/s41421-022-00517-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, T. et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624, 630–638 (2023). This study reports inhaled dry powder vaccine formulation that induces respiratory mucosal immunity, eliminating the need for cold storage and needles.</Citation><ArticleIdList><ArticleId IdType="pubmed">38093012</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06809-8</ArticleId></ArticleIdList></Reference><Reference><Citation>vander Straeten, A. et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat. Biotechnol. 42, 510–517 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-023-01774-z</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>